Related Experiment Videos
Excessive daytime sleepiness in parkinsonism
1Fédération des Pathologies du Sommeil, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. isabelle.arnulf@psl.ap-hop-paris.fr
Sleep Medicine Reviews
|May 17, 2005
Summary
Excessive daytime sleepiness (EDS) affects many Parkinson's disease (PD) patients, linked to disease severity and medications. Specific tests reveal sleep disorders, treatable with medication adjustments or modafinil.
Area of Science:
- Neurology
- Sleep Medicine
Background:
- Excessive daytime sleepiness (EDS) impacts 20-50% of Parkinson's disease (PD) patients.
- Sleep attacks (SA) are infrequent, but EDS is linked to advanced PD, higher levodopa doses, and dopamine agonist use.
Purpose of the Study:
- To explore the prevalence and characteristics of EDS and SA in Parkinson's disease.
- To identify risk factors and diagnostic tools for sleep disturbances in PD.
- To evaluate treatment strategies for EDS in PD patients.
Main Methods:
- Review of patient data including disease stage, medication, Epworth Sleepiness Scale (ESS) scores.
- Utilizing polysomnography (PSG) to assess sleep apnea.
- Employing multiple sleep latency tests (MSLT) to identify narcolepsy-like phenotypes.
Main Results:
- EDS is associated with advanced PD, higher levodopa-equivalent doses, and dopamine agonist use.
- Sleep apnea occurs in 20% of PD patients; a narcolepsy-like phenotype is seen in severe EDS cases.
- Dopamine agonist adjustment or modafinil showed benefit for EDS.
Conclusions:
- EDS is a significant issue in Parkinson's disease, potentially indicating sleep-wake system dysfunction.
- PSG and MSLT are valuable for diagnosing sleep disorders in PD.
- Medication management and modafinil are effective treatments for EDS in PD and atypical parkinsonism.